이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

HBM Holdings 과거 수익 실적

과거 기준 확인 2/6

HBM Holdings은 연평균 10.4%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 수입이 증가했으며, 연간 11.7%였습니다. 매출은 연평균 58.1%의 비율로 증가했습니다. HBM Holdings의 자기자본이익률은 19%이고 순이익률은 25.5%입니다.

주요 정보

10.4%

수익 성장률

40.6%

EPS 성장률

Biotechs 산업 성장	11.0%
매출 성장률	58.1%
자기자본 수익률	19.0%
순이익	25.5%
최근 수익 업데이트	31 Dec 2023

최근 과거 실적 업데이트

Recent updates

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

May 23

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

Apr 12

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jan 01

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

Feb 08

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

May 30

Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Apr 07

Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

Mar 31

What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?

Mar 10

수익 및 비용 분석

HBM Holdings 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SEHK:2142 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Dec 23	90	23	21	45
30 Sep 23	72	-19	21	62
30 Jun 23	54	-61	21	80
31 Mar 23	47	-99	24	108
31 Dec 22	41	-137	27	135
30 Sep 22	35	-143	35	142
30 Jun 22	30	-149	43	150
31 Mar 22	17	-144	42	128
31 Dec 21	4	-138	40	107
30 Sep 21	7	-224	46	94
30 Jun 21	10	-310	53	81
31 Mar 21	12	-303	50	68
31 Dec 20	14	-296	46	55
30 Sep 20	13	-187	28	46
30 Jun 20	11	-78	11	37
31 Mar 20	8	-73	11	43
31 Dec 19	5	-67	11	49
31 Dec 18	1	-35	6	32

양질의 수익: 2142 의 비현금 수입 수준이 높습니다.

이익 마진 증가: 2142 는) 과거에 수익을 냈습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 2142 지난 5년 동안 수익을 창출하여 매년 10.4% 수익을 올렸습니다.

성장 가속화: 2142 지난해 흑자를 기록해 5년 평균과 비교하기 어려운 수익 성장률을 보이고 있습니다.

수익 대 산업: 2142 작년에 수익을 올렸기 때문에 지난 해 수익 성장을 Biotechs 업계( 22.1% )와 비교하기가 어렵습니다.

HBM Holdings 과거 수익 실적

과거 기준 확인 2/6

주요 정보

최근 과거 실적 업데이트

Full year 2023 earnings released: EPS: US$0.03 (vs US$0.19 loss in FY 2022)

HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: US$0.004 (vs US$0.10 loss in 1H 2022)

HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

First half 2022 earnings released: US$0.10 loss per share (vs US$0.084 loss in 1H 2021)

Recent updates

Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 17%

New minor risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

HBM Holdings Limited, Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: EPS: US$0.03 (vs US$0.19 loss in FY 2022)

HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S

HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

HBM Holdings Limited Announces Executive Changes

New major risk - Revenue and earnings growth

Forecast to breakeven in 2023

Consensus EPS estimates upgraded to US$0.05 loss

First half 2023 earnings released: EPS: US$0.004 (vs US$0.10 loss in 1H 2022)

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

New minor risk - Share price stability

HBM Holdings Limited Announces Board Changes

National Medical Products Administration of China Accepts Biologics License Application for HBM Holdings Limited's Batoclimab for Treatment of gMG

HBM Holdings Limited Appoints Steve Arkinstall as Chief Scientific Advisor of Nona Biosciences

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-In-Class Anti-B7H7 (HHLA2) Antibody HBM1020

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

Consensus revenue estimates increase by 28%

Consensus estimates of losses per share improve by 36%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Hbm Holdings Limited Announces Food and Drug Administration of the United States Investigational New Drug Clearance for HBM1020 Clinical Trial Initiation

Hbm Holdings Limited Announces Results from Phase I Clinical Trial of Porustobart (Hbm4003)In Combination with Toripalimab in Advanced Melanoma

WuXi Vaccines (Hong Kong) Limited entered into an agreement to acquire Manufacturing facility in Suzhou from HBM Holdings Limited (SEHK:2142).

Less than half of directors are independent

HBM Holdings Limited Appoints Mr. Weihao Xu as Chief Business Officer

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

Hbm Holdings Limited Announces Closing the Study of Phase III Clinical Trial of Tanfanercept (Hbm9036)

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

Consensus forecasts updated

First half 2022 earnings released: US$0.10 loss per share (vs US$0.084 loss in 1H 2021)

Hbm Holdings Limited Announces Completion of First Dosing of Last Patient with Hbm4003 Phase Ib Trial

Harbour BioMed Announces the Preclinical Results of Porustobart

HBM Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration

HBM Holdings Limited Announces IND Approval for Commencement of Phase I Trial of B7H4X4-1BB Bispecific Antibody in China

Hbm Holdings Limited Announces Data Release of Next-Gen Ctla-4 Antibody At Asco 2022

HBM Holdings Limited Announces That Dosing of First Patient in Phase I Trial of B7h4x4-1Bb Bispecific Antibody Hbm7008 Has Been Completed

Consensus forecasts updated

Hbm Holdings Limited Announces Data Release Forecast of Hbm4003 At ASCO 2022

HBM Holdings Limited Announces Board Changes

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

Less than half of directors are independent

Harbour BioMed Appoints Humphrey Gardner as Chief Medical Officer

Consensus revenue estimates increase by 302%

Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia

HBM Holdings Limited Announces Approval of Investigational New Drug Application for HBM9378 by National Medical Products Administration of the People's Republic of China

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

HBM Holdings Limited Announces Completion of First Interim Analysis of Phase III Clinical Trial of Tanfanercept (HBM9036)

Founder recently bought HK$1.0m worth of stock

HBM Holdings Limited Announces Completion of First Dosing of First Patient with Two HBM4003 Phase I Trials

HBM Holdings Limited Announces Completion of First Dosing of First Patient with Batoclimab (Hbm9161) Phase III Trial for Treatment of Generalized Myasthenia Gravis

Harbour Biomed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

HBM Holdings Limited Announces Chinese Regulatory Approval of Two Ind Applications for Next-Generation Anti-Ctla-4 Antibody Hbm4003

First half 2021 earnings released: US$0.084 loss per share (vs US$0.39 loss in 1H 2020)

HBM Holdings Limited Receives National Medical Products Administration of the People's Republic of China Approval of Investigational New Drug Application to Begin Phase II Clinical Trial of HBM9161 in Chronic Inflammatory Demyelinating Polyneuropathy

Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

HBM Holdings Limited Provides Update on Ongoing Clinical Studies Forbatoclimab (HBM9161)

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody

Executive Director, Chief Strategy Officer & Head of U.S. Operations has left the company